Amy Carleton Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8758 Egan Dr, Savage, MN 55378 Phone: 952-443-9888 Fax: 952-443-9804 |
Ruth Froese, OTR Occupational Therapist - Physical Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 14954 Valley View Dr, Savage, MN 55378 Phone: 952-447-0114 |
Megan Aarsvold, MA OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 14441 Quebec Ave, Savage, MN 55378 Phone: 320-491-9325 |
Hillary Anderson Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8758 Egan Dr, Savage, MN 55378 Phone: 952-226-2999 Fax: 952-443-9804 |
Ms. Chelsea Marie Krob, MOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 14906 Creditview Dr, Savage, MN 55378 Phone: 651-485-6136 |
Alyssa Jeanne Norenberg, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8758 Egan Dr, Savage, MN 55378 Phone: 952-443-9888 |
News Archive
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Changes to legislation that govern regulated health professionals in Ontario open the door to improvements in patient care but stop short of the kind of change that would further reduce wait times and improve access for the public, according to the top professional nursing organization.
Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue of the European Journal of Cancer on cancer prevention, published today.
A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.
› Verified 2 days ago